Galcanezumab for the prevention of migraine

Lindsay M. Frerichs, Deborah I. Friedman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.

Original languageEnglish
Pages (from-to)101-112
Number of pages12
JournalPain Management
Issue number2
StatePublished - Mar 2021


  • CGRP monoclonal antibody
  • galcanezumab
  • headache
  • migraine
  • prevention
  • treatment


Dive into the research topics of 'Galcanezumab for the prevention of migraine'. Together they form a unique fingerprint.

Cite this